Synthesis, Structure, and Biologic Activity of Some Copper, Nickel, Cobalt, and Zinc Complexes with 2-Formylpyridine N 4-Allylthiosemicarbazone. 2022

Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
Laboratory of Advanced Materials in Biofarmaceutics and Technics, Moldova State University, 60 Mateevici Street, MD 2009, Chisinau, Moldova.

A series of zinc(II) ([Zn(H2O)(L)Cl] (1)), copper (II) ([Cu(L)Cl] (2), [Cu(L)Br] (3), [Cu2(L)2(CH3COO)2]·4H2O (4)), nickel(II) ([Ni(HL)2]Cl2·H2O (5)), and cobalt(III) ([Co(L)2]Cl (6)) complexes were obtained with 2-formylpyridine N 4-allylthiosemicarbazone (HL). In addition another two thiosemicarbazones (3-formylpyridine N 4-allylthiosemicarbazone (HL a) and 4-formylpyridine N 4-allylthiosemicarbazone (HL b)) have been obtained. The synthesized thiosemicarbazones have been studied using 1H and 13C NMR spectroscopy, IR spectroscopy, and X-ray diffraction analysis. The composition and structure of complexes were studied using elemental analysis, IR and UV-Vis spectroscopies, molar conductivity, and magnetic susceptibility measurements. Single crystal X-ray diffraction analysis elucidated the structure of thiosemicarbazones HL, HL a, and HL b, as well as complexes 4 and 5. The antiproliferative properties of these compounds toward a series of cancer cell lines (HL-60, HeLa, BxPC-3, RD) and a normal cell line (MDCK) have been investigated. The nickel complex shows high selectivity (SI > 1000) toward HL-60 cell line and is the least toxic. The zinc complex shows the highest selectivity toward RD cell line (SI = 640). The copper complexes (2-4) are the most active molecular inhibitors of proliferation of cancer cells, but exhibit not such a high selectivity and are significantly more toxic. Zinc and copper complexes manifest high antibacterial activity. It was found that calculated at B3LYP level of theory different reactivity descriptors of studied compounds strongly correlate with their biological activity.

UI MeSH Term Description Entries

Related Publications

Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
March 2009, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy,
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
December 2008, Journal of enzyme inhibition and medicinal chemistry,
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
March 2019, Chemical reviews,
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
February 2004, Journal of enzyme inhibition and medicinal chemistry,
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
July 2002, Journal of inorganic biochemistry,
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
January 2024, Materials (Basel, Switzerland),
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
January 2005, Pakistan journal of pharmaceutical sciences,
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
April 2009, Journal of enzyme inhibition and medicinal chemistry,
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
August 2010, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy,
Vasilii Graur, and Yurii Chumakov, and Olga Garbuz, and Christelle Hureau, and Victor Tsapkov, and Aurelian Gulea
February 1996, Journal of inorganic biochemistry,
Copied contents to your clipboard!